Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HemaMax™ (rHuIL-12) in Healthy Subjects

NCT02343133 is registered in ClinicalTrials.gov with Neumedicines Inc. as lead sponsor.

NCT NCT02343133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02343133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HemaMax™ (rHuIL-12) in Healthy Subjects
Lead sponsor
Neumedicines Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2015
Completion date
April 30, 2016
Enrollment
200 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic syndrome due to acute radiation syndrome